The CHST6 gene helps make a sugar rich material in the cornea, the clear front window of the eye, that keeps it transparent and well organized. If this gene does not work properly, the cornea can slowly become cloudy as abnormal material builds up, which may lead to blurred vision, glare, and worsening sight over time. Pathogenic variants in the CHST6 gene are a known cause of macular corneal dystrophy, an inherited eye condition that often begins in childhood or early adulthood.
What is a gene?
Genes are stretches of DNA that give your cells instructions for making molecules or directing processes in the body. Some genes carry the information needed to produce proteins, the parts of cells that do much of the work. Others mainly regulate when certain processes take place, where they happen, and how active they are. Taken together, genes influence how the body develops and functions, and they can affect how you respond to food, stress, and medications. You can find more on this topic in the LearnHub.
Overview
CHST6Gene function
What if the gene works
The CHST6 gene helps the clear front surface of the eye stay transparent. It supports normal keratan sulfate, a sugar material that helps organize the cornea and hold the right amount of water.
Risk
What if the gene does not work
When the CHST6 gene does not work properly, it can cause macular corneal dystrophy, with cloudy corneas and gradually reduced vision. Milder to more severe variants can influence how early vision changes appear and how much the cornea is affected.
Treatment
What does that mean for your treatment
For pathogenic variants in the CHST6 gene, no CHST6 specific drug treatment is currently established. Care is guided by the eye findings: lubricating drops can help surface discomfort, and if corneal clouding significantly affects vision, corneal transplantation is the standard management approach.
Conditions associated with CHST6
Gene function
What if the gene works
In the clear front surface of the eye, the CHST6 gene helps maintain the special material that keeps the cornea organized and transparent. Its protein adds small chemical tags called sulfate groups to certain sugar chains. This steady process supports the cornea’s normal structure and clarity.
One role of the CHST6 gene is to add sulfate groups to keratan sulfate, a sugar rich material in the cornea. These small tags help that material keep the right chemical properties for normal eye tissue.
In the cornea, this gene helps shape the matrix, the supportive material between cells. That organized framework helps the tissue stay evenly arranged and suited for clear light passage.
By modifying keratan sulfate, the CHST6 gene supports normal corneal transparency. This helps explain how the CHST6 gene supports corneal clarity in everyday vision.
What is a variant?
A genetic variant is a minor alteration in the DNA sequence within a gene. These changes are common and help shape normal human diversity, such as differences in appearance, metabolism, or the way the body reacts to environmental influences. Many variants do not cause any noticeable effects and are simply part of natural genetic variation. At times, though, a variant changes how a gene works more significantly and can contribute to or cause a genetic condition.
Genetic variants
What if the gene does not work
CHST6 gene variants linked to macular corneal dystrophy reduce or stop the enzyme made from this gene. Some change a protein building block and leave partial activity, while severe variants can truncate the protein or disrupt splicing (how the gene's message is assembled), leaving little or no working enzyme. This creates a spectrum from milder to more severe functional loss, and greater loss of activity often lines up with earlier or more marked corneal changes, although effects can vary.
How variants are linked to conditions
Variants in the CHST6 gene cause macular corneal dystrophy, a rare inherited eye condition that makes the cornea gradually become cloudy. This CHST6 gene link to macular corneal dystrophy is well established in human genetics. People with this condition may develop blurred vision, increasing glare, and changes that can affect one or both eyes over time. In many cases, finding two disease-causing variants in the CHST6 gene can confirm the diagnosis.
A variant is not necessarily a diagnosis
Variants in genes are a usual part of human biology and are widespread in the general population. Most do not have a direct effect on health and instead reflect normal human diversity. For many genes, having a variant associated with a condition suggests a possible link rather than a definite diagnosis, especially when several genes and environmental factors are involved. In some situations, though, one well-characterized variant in a specific gene is enough to confirm a diagnosis.
Are there things that can increase or change my risk?
For CHST6, risk is mainly determined by genetics: people usually develop the related cornea condition only if they inherit changed copies from both parents. Family history and parents being blood relatives can raise the chance of inheriting this pattern, while there is not enough evidence that lifestyle changes lower the risk.
Inheritance of CHST6 variants
CHST6-related macular corneal dystrophy follows an autosomal recessive inheritance pattern. This means a person usually inherits one CHST6 variant from each parent, and parents who each carry one variant are typically unaffected carriers; with each pregnancy, there is a 25% chance of having an affected child, a 50% chance of having a carrier child, and a 25% chance of having a child without the familial variants. In practical terms, how CHST6 variants are inherited means the condition can appear in a family even when there is no previous history of corneal disease.
What does my CHST6 result mean for my family?
For CHST6, family impact is usually discussed in a recessive pattern. Brothers and sisters of someone with a disease-causing CHST6 result may also be affected or may carry the same gene change without having symptoms. Parents are often healthy carriers, and other relatives may also be carriers, especially on the same side of the family. This can matter for future children in the family.
Genetic information
Genetic testing
How you find out about variants
Genetic testing for CHST6 variants uses a blood or saliva sample to read the CHST6 gene and look for changes linked to macular corneal dystrophy. It can confirm whether a person carries disease-causing variants, and results may also show no relevant variant or a variant of uncertain significance.
When should I consider getting a genetic test?
Genetic testing for the CHST6 gene may be worth considering if you or your child has unexplained cloudy corneas, worsening blurry vision, or a diagnosis of macular corneal dystrophy, a rare inherited eye condition. It can also help if this condition runs in your family or if both parents are known carriers.
A genetic result is only one part of your health story
Genetic test results can provide useful information, but how much they reveal varies by the condition and the type of variant involved. Many other factors, including age, environment, lifestyle, and medical history, also shape how the body works over time. In some conditions, especially those influenced by many genes, genetic information provides context rather than certainty and is best understood along with other parts of care. In other situations, a genetic result can offer a clear answer. In areas like medication response, genetic results can also help put individual experiences into perspective.
Pharmacogenetics
How variants shape your response to medicine
Genetic variation can affect how people respond to medicines. This helps explain why the same treatment works well for one person, seems less effective for another, or causes more side effects in someone else. Small inherited differences can change how the body breaks down a drug, moves it through the body, or responds to it at its target, and this kind of variation is common.
What is Pharmacogenetics?
Pharmacogenetics examines how differences in genes can affect the way a person responds to medication. It studies the relationship between genes and drugs to help explain why the same treatment can work differently from one person to another. For many medicines, genes can influence both how strongly a drug works and how the body processes it. This information can support more informed, individualized treatment decisions. More detail on this topic is available in the LearnHub.
Drugs influenced by the CHST6 gene
When should I seek medical advice?
There is not yet a broadly confirmed role for this gene in guiding medication choice or dose, so general questions about medicines, side effects, or changes in treatment are best discussed with your doctor.
History
CHST6 entered the genetics literature when researchers studying families with macular corneal dystrophy traced the condition to chromosome 16. In recent decades, awareness of this gene’s role has grown as the exact gene was identified in 2000, helping connect a long recognized corneal condition to a specific inherited cause. From these first observations, research expanded steadily, and scientists described many different CHST6 variants in affected families around the world. This helped refine diagnosis and separated macular corneal dystrophy more clearly from other corneal conditions that can look similar at first. Over time, genetic studies also showed that changes in CHST6 can vary between families, which added depth to the clinical picture.